(19)
(11) EP 4 182 445 A2

(12)

(88) Date of publication A3:
24.02.2022

(43) Date of publication:
24.05.2023 Bulletin 2023/21

(21) Application number: 21842986.8

(22) Date of filing: 19.07.2021
(51) International Patent Classification (IPC): 
C12N 5/078(2010.01)
C12N 9/22(2006.01)
A61P 7/06(2006.01)
C12N 15/113(2010.01)
C12N 15/86(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 14/4703; C07K 16/2818
(86) International application number:
PCT/US2021/042152
(87) International publication number:
WO 2022/016140 (20.01.2022 Gazette 2022/03)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 17.07.2020 US 202063053308 P
20.08.2020 US 202063068150 P

(71) Applicant: The Children's Medical Center Corporation
Boston, MA 02115 (US)

(72) Inventors:
  • BAUER, Daniel, E.
    Cambridge, MA 02138 (US)
  • VINJAMUR, Divya
    Boston, MA 02115 (US)

(74) Representative: Dolphin, Kirsty Mairi et al
Venner Shipley LLP 200 Aldersgate
London EC1A 4HD
London EC1A 4HD (GB)

   


(54) TARGETING ZNF410 FOR FETAL HEMOGLOBIN INDUCTION IN BETA-HEMOGLOBINOPATHIES